-- Theseus Stockholders to Receive $4.05 Per Share in Cash Plus Contingent Value Right --

--这些美国股东将获得每股4.05美元的现金加上或有价值权利--

CAMBRIDGE, Mass., Feb. 14, 2024 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ('Theseus' or the 'Company'), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced that Concentra Biosciences, LLC ('Concentra') through its wholly owned subsidiary, Concentra Merger Sub II, Inc.

马萨诸塞州剑桥，2024年2月14日/新闻专线/--Theseus Pharmaceuticals，Inc.（纳斯达克：THRX）（“Theseus”或“公司”），一家临床阶段的生物制药公司，专注于通过发现，开发和商业化转化靶向疗法来改善癌症患者的生活，今天宣布，Concentra Biosciences，LLC（“Concentra”）通过其全资子公司Concentra Merge Sub II，Inc。

('Merger Sub'), has successfully completed the previously announced tender offer to acquire all outstanding shares of Theseus common stock for a price per share of (i) $4.05 in cash (the 'Cash Amount'), plus (ii) one non-tradeable contingent value right per share (each, a 'CVR' and each CVR together with the Cash Amount, the 'Offer Price') representing the right to receive 80% of the net proceeds from any license or disposition of certain of Theseus' programs effected within 180 days of the close of the merger and 50% of the potential aggregate value of certain specified potential cost savings realized within 180 days of the close of the merger, pursuant to a Contingent Value Rights Agreement..

（“合并子公司”）已成功完成先前宣布的收购要约，以每股（i）4.05美元现金（“现金金额”）的价格收购美国普通股的所有已发行股份，再加上（ii）每股一项不可交易或有价值权（每项“CVR”和每项CVR以及现金金额（“要约价格”）根据或有价值权利协议，代表有权从合并结束后180天内生效的某些特修斯计划的任何许可或处置中获得80%的净收益，以及在合并结束后180天内实现的某些特定潜在成本节约的潜在总价值的50%。。

The tender offer and related withdrawal rights expired at 6:00 p.m. Eastern Time on February 13, 2024 (the 'Expiration Date'). As of the Expiration Date, a total of 37,211,244 shares of Theseus common stock were validly tendered, and not validly withdrawn, representing approximately 83.3% of the outstanding shares of Theseus common stock as of the Expiration Date.

投标报价和相关撤回权于2024年2月13日东部时间下午6:00到期（“到期日”）。截至到期日，共有37211244股美国普通股被有效投标，未被有效撤回，约占截至到期日美国普通股流通股的83.3%。

As of the Expiration Date, the number of shares validly tendered in accordance with the terms of the tender offer and not validly withdrawn satisfied the minimum tender condition, and all other conditions to the tender offer were satisfied or waived. Immediately after the Expiration Date, Merger Sub irrevocably accepted for payment all shares validly tendered and not validly withdrawn, and expects to promptly pay for such shares..

截至到期日，根据要约条款有效投标且未有效撤回的股份数量满足最低投标条件，并且满足或放弃了要约的所有其他条件。到期日后，合并子公司立即不可撤销地接受所有有效投标且未有效撤回的股份的付款，并期望立即支付此类股份。。

Following the closing of the tender offer, Merger Sub merged with and into Theseus (the 'Merger') and all shares of Theseus common stock that had not been validly tendered were converted into the right to receive the Offer Price. As a result of the Merger, Theseus became a wholly owned subsidiary of Concentra.

收购要约结束后，与特修斯合并并并入特修斯的合并（“合并”）以及未经有效投标的特修斯普通股的所有股份均被转换为获得要约价格的权利。合并后，特修斯成为康森特拉的全资子公司。

Prior to the opening of trading on The Nasdaq Stock Market LLC ('Nasdaq') on February 14, 2024, all shares of Theseus common stock will cease trading on Nasdaq, and Theseus intends promptly to cause such shares to be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934, as amended..

在纳斯达克股票市场有限责任公司（“纳斯达克”）于2024年2月14日开始交易之前，特修斯普通股的所有股票将停止在纳斯达克交易，特修斯打算立即将这些股票从纳斯达克摘牌，并根据经修订的《1934年证券交易法》注销登记。。

Advisors

顾问

Leerink Partners acted as exclusive financial advisor and Goodwin Procter LLP acted as legal counsel to Theseus. Gibson, Dunn & Crutcher LLP acted as legal counsel to Concentra.

Leerink Partners担任特修斯的独家财务顾问，Goodwin Procter LLP担任特修斯的法律顾问。Gibson，Dunn&Crutcher LLP担任Concentra的法律顾问。

About Theseus Pharmaceuticals, Inc.

关于Theseus Pharmaceuticals，Inc。

Theseus is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies.

Theseus是一家临床阶段的生物制药公司，专注于通过发现，开发和商业化转化靶向疗法来改善癌症患者的生活。

Cautionary Notice Regarding Forward-Looking Statements

关于前瞻性声明的警示

This communication contains 'forward-looking statements' relating to the acquisition of Theseus by Theseus. Such forward-looking statements include, but are not limited to, statements regarding the payment and timing of payment of the Offer Price to former Theseus common stockholders and the ability and timing of delisting of Theseus' common stock.

本通信包含与特修斯收购特修斯有关的“前瞻性声明”。此类前瞻性声明包括但不限于关于向前特修斯普通股股东支付要约价格和支付时间以及特修斯普通股退市能力和时间的声明。

These statements may be identified by their use of forward-looking terminology including, but not limited to, 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'goal,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' and 'would,' and similar words expressions are intended to identify forward-looking statements.

这些陈述可以通过使用前瞻性术语来识别，这些术语包括但不限于“预期”，“相信”，“继续”，“可能”，“估计”，“预期”，“目标”，“打算”，“可能”，“可能”，“计划”，“潜力”，“预测”，“项目”，“应该”，“目标”，“意志”和“将会”，以及类似的词语来识别前瞻性陈述。

Forward-looking statements are neither historical facts nor assurances of future performance and involve risks and uncertainties that could cause actual results to differ materially from those projected, expressed or implied by such forward-looking statements. Although Theseus believes that the expectations reflected in such forward-looking statements are reasonable, it cannot guarantee future events, results, actions, levels of activity, performance or achievements, business and market conditions and the timing and results of any developments.

前瞻性陈述既不是历史事实，也不是未来业绩的保证，涉及的风险和不确定性可能导致实际结果与此类前瞻性陈述所预测、明示或暗示的结果存在重大差异。虽然特修斯认为这些前瞻性声明中反映的期望是合理的，但它不能保证未来的事件、结果、行动、活动水平、绩效或成就、业务和市场状况以及任何发展的时间和结果。

Additional factors that may affect the future results of Theseus are set forth in Theseus' filings with the U.S. Securities and Exchange Commission (the 'SEC'), including Theseus' most recently filed Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, which are available on the SEC's website at www.sec.gov.

可能影响特修斯未来业绩的其他因素载于特修斯向美国证券交易委员会（“SEC”）提交的文件中，包括特修斯最近提交的10-K表年度报告、随后提交的10-Q表季度报告、8-K表当前报告以及向SEC提交的其他文件，这些文件可在SEC网站www.SEC.gov上查阅。

As a result of such risks and uncertainties, actual results may differ materially from any future results, performance or achieveme.

由于此类风险和不确定性，实际结果可能与任何未来结果、绩效或成就存在重大差异。

The forward-looking statements contained in this release are made as of the date hereof, and Theseus undertakes no obligation to update any forward-looking statements, whether as a result of future events, new information or otherwise, except as expressly required by law. All forward-looking statements in this document are qualified in their entirety by this cautionary statement..

本新闻稿中包含的前瞻性声明是在本新闻稿发布之日做出的，特修斯没有义务更新任何前瞻性声明，无论是由于未来事件、新信息还是其他原因，除非法律明确要求。本警示声明对本文件中的所有前瞻性陈述进行了整体限定。。

For further information, please contact:

欲了解更多信息，请联系：

Theseus Pharmaceuticals, Inc.IR@theseusrx.com

Theseus Pharmaceuticals，Inc.IR@theseusrx.com

SOURCE Theseus Pharmaceuticals

来源Theseus Pharmaceuticals